Abstract: A changing table comprises a wall assembly and a tray assembly. The wall assembly is capable of mounting to a wall, and the tray assembly is pivotally attached to the wall assembly such that the wall assembly and tray assembly form a changeable angle ? in between them. The tray assembly comprises an exterior first surface and an interior second surface. The interior second surface comprises a cushion and is configured to receive an infant.

Abstract: A changing table comprises a wall assembly and a tray assembly. The wall assembly is capable of mounting to a wall, and the tray assembly is pivotally attached to the wall assembly such that the wall assembly and tray assembly form a changeable angle ? in between them. The tray assembly comprises an exterior first surface and an interior second surface. The interior second surface comprises a cushion and is configured to receive an infant.

Abstract: A changing table comprises a wall assembly and a tray assembly. The wall assembly comprises wall housing, a transparent-to-UV-light panel, and a UV light source. The wall assembly and tray assembly form a changeable angle ? in between them. The tray assembly comprises an exterior first surface and an interior second surface. The second surface is configured to receive an infant and at least a portion of UV light generated by the UV light source.

Abstract: A changing table comprises a wall assembly and a tray assembly. The wall assembly comprises wall housing, a transparent-to-UV-light panel, and a UV light source. The wall assembly and tray assembly form a changeable angle ? in between them. The tray assembly comprises an exterior first surface and an interior second surface. The second surface is configured to receive an infant and at least a portion of UV light generated by the UV light source.

Abstract: A system for conditioning drilling fluid includes a conditioning device having a first conduit configured to receive the drilling fluid, a flow restriction disposed adjacent the first conduit, the flow restriction comprising a fluid inlet and a fluid outlet, an impact plate disposed downstream of the flow restriction, a first chamber disposed between the flow restriction and the impact plate, and a second chamber disposed downstream of the impact plate, wherein the first chamber is fluidly connected to the second chamber. A method for conditioning drilling fluid using a conditioning device, includes pumping a drilling fluid through a flow restriction, accelerating the drilling fluid into a mixing chamber, subjecting the drilling fluid to elongational shearing, decelerating the drilling fluid against an impact plate, subjecting the drilling fluid to impact shearing, and emptying drilling fluid from the mixing chamber.

Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.

Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.

Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.

Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.

Abstract: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.

Abstract: A deadbolt lock includes a deadbolt, a user rotatable actuator, and a lock interface. The user rotatable actuator is operatively connected with the deadbolt for movement of the deadbolt between locked and unlocked conditions when the actuator is changed from an inoperable condition to an operable condition. The lock interface is configured to change the actuator from the inoperable condition to the operable condition in response to proper user manipulation of the lock interface.

Abstract: Embodiments include sets of nestable containers with each container having a cover comprises a fold. The covers are disposable between two of the nestable containers when the containers are nested with each other. Uses of the containers include, for example, food, craft, and home storage.

Abstract: The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

Abstract: A liquid fuel collecting and damming assembly located in a vehicle fuel tank to aid the intake of fuel to the engine by elevating the level of fuel about the fuel inlet particularly when the liquid level in the tank is relatively low. The assembly provides an open-ended cylindrical wall which is supported on the fuel tank bottom so that the inlet to the fuel line extends through the resultant open top so as to extend downward toward the bottom. A fuel return conduit extends through the collector assembly's wall and has an outlet end portion spaced vertically upward from the inlet portion so that fuel is discharged therethrough into the collector assembly and enters at an elevated level. The fuel supply in the collector assembly remains at the elevated level with respect to fuel in the tank at a low level condition due to the raised outlet portion of the return conduit.